References
- Bauchau V, Durham SR. Epidemiological characterization of the intermittent and persistent types of allergic rhinitis. Allergy 2005;60:350-3
- Bousquet J, Khaltaev N, Cruz AA, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy 2008;63(Suppl 86):8-160
- Howarth PH. Antihistamines in rhinoconjunctivitis. In: Simons FER (ed.) Histamine and H1-Antihistamines in Allergic Disease, 2nd edn. New York: Marcel Dekker Inc., 2002:179-200
- Bachert C, Kuna P, Sanquer F, et al. Comparison of the efficacy and safety of bilastine 20 mg vs desloratadine 5 mg in seasonal allergic rhinitis patients. Allergy 2009;64:158-65
- Kuna P, Bachert C, Nowacki Z, et al. Efficacy and safety of bilastine 20 mg compared with cetirizine 10 mg and placebo for the symptomatic treatment of seasonal allergic rhinitis: a randomized, double-blind, parallel-group study. Clin Exp Allergy 2009;39:1338-47
- Zuberbier T, Oanta A, Bogacka E, et al. Comparison of the efficacy and safety of bilastine 20 mg vs levocetirizine 5 mg for the treatment of chronic idiopathic urticaria: a multi-centre, double-blind, randomized, placebo-controlled study. Allergy 2010;65:516-28
- Bachert C, Kuna P, Zuberbier T. Bilastine in allergic rhinitis and urticaria. Allergy 2010;65(Suppl 93):1-13
- Jauregizar N, de la Fuente L, Lucero ML, et al. Pharmacokinetic–pharmacodynamic modelling of the antihistaminic (H1) effect of bilastine. Clin Pharmacokinet 2009;48:543-54
- Corcóstegui R, Labeaga L, Innerárity A, et al. In vivo pharmacological characterisation of bilastine, a potent and selective histamine H1 receptor antagonist. Drugs R D 2006;7:219-31
- Corcóstegui R, Labeaga L, Innerárity A, et al. Preclinical pharmacology of bilastine, a new selective histamine H1 receptor antagonist: receptor selectivity and in vitro antihistaminic activity. Drugs R D 2005;6:371-84
- Mansmann H Jr, Altman RA, Berman BA, et al. Efficacy and safety of cetirizine therapy in perennial allergic rhinitis. Ann Allergy 1992;68:348-53
- Murris-Espin M, Melac M, Charpentier JC, et al. Comparison of efficacy and safety of cetirizine and ebastine in patients with perennial allergic rhinitis. Ann Allergy Asthma Immunol 1998;80:399-403
- Bousquet J, Duchateau J, Pignat JC, et al. Improvement of quality of life by treatment with cetirizine in patients with perennial allergic rhinitis as determined by a French version of the SF-36 questionnaire. J Allergy Clin Immunol 1996;98:309-16
- Benninger M, Farrar JR, Blaiss M, et al. Evaluating approved medications to treat allergic rhinitis in the United States: an evidence-based review of efficacy for nasal symptoms by class. Ann Allergy Asthma Immunol 2010;104:13-29
- Lu S, Malice MP, Dass SB, et al. Clinical studies of combination montelukast and loratadine in patients with seasonal allergic rhinitis. J Asthma 2009;46:878-83
- Mansfield LE, Hampel F, Haeusler JM, et al. Study of levocetirizine in seasonal allergic rhinitis. Curr Med Res Opin 2010;26:1269-75
- Baraniuk JN. The placebo effect: plugging the nostrils of unmet needs. Curr Allergy Asthma Rep 2009;9:149-52